scispace - formally typeset
R

Rui Henrique

Researcher at University of Porto

Publications -  400
Citations -  12204

Rui Henrique is an academic researcher from University of Porto. The author has contributed to research in topics: Cancer & Prostate cancer. The author has an hindex of 53, co-authored 351 publications receiving 9946 citations. Previous affiliations of Rui Henrique include Ghent University & Katholieke Universiteit Leuven.

Papers
More filters
Journal ArticleDOI

Quantitation of GSTP1 methylation in non-neoplastic prostatic tissue and organ-confined prostate adenocarcinoma.

TL;DR: Quantitation of GSTP1 methylation accurately discriminates between normal hyperplastic tissue and prostatic carcinoma in small samples of prostate tissue and may augment the standard pathologic/histologic assessment of the prostate.
Journal ArticleDOI

TMPRSS2-ERG Gene Fusion Causing ERG Overexpression Precedes Chromosome Copy Number Changes in Prostate Carcinomas and Paired HGPIN Lesions

TL;DR: It is demonstrated for the first time that the TMPRSS2-ERG fusion gene can be detected in a proportion of HGPIN lesions and that this molecular rearrangement is an early event that may precede chromosome-level alterations in prostate carcinogenesis.
Journal ArticleDOI

A quantitative promoter methylation profile of prostate cancer.

TL;DR: The data demonstrate the existence of a progressive increase of promoter methylation levels of several cancer-related genes in prostate carcinogenesis, providing additional markers to augment molecular detection of prostate carcinoma.
Journal ArticleDOI

Quantitative methylation-specific polymerase chain reaction gene patterns in urine sediment distinguish prostate cancer patients from control subjects.

TL;DR: The data support further development of the noninvasive QMSP assay in urine DNA for early detection and surveillance of prostate cancer and recommend a combination of only four genes to detect 87% of prostate cancers with 100% specificity.
Journal ArticleDOI

Mitochondrial mutations in early stage prostate cancer and bodily fluids.

TL;DR: Although mitochondrial mutations are less common in prostate adenocarcinoma, they occur early in cancer progression and they can be detected in bodily fluids of early stage disease patients, and the identification of MtDNA mutations may complement other early detection approaches for prostate cancer.